Omeros (NASDAQ:OMER) Q3 Revenue Miss Overshadows EPS Beat as YARTEMLEA Launch Faces Scrutiny
Omeros falls 10% despite revenue beat
Omeros (OMER) Surpasses Q3 Earnings and Revenue Estimates
Omeros: Q3 Earnings Snapshot
Omeros Corporation Reports Third Quarter 2026 Financial Results
Omeros (OMER) Stock May Be Undervalued After Investor Fraud Probe
Omeros Corporation to Announce Third Quarter Financial Results on November 16, 2026
Omeros Shares Slide After CHMP Upholds Negative Opinion On Drug; Analyst Sees Buying Opportunity At $16
Omeros Shares Fall 4% as European Regulators Uphold Negative Opinion on Narsoplimab
Omeros shares slide following European regulatory setback for Narsoplimab
Omeros Faces Second Rejection Of Narsoplimab In Europe – OMER Stock Falls Below Key Support For First Time In Nearly 3 Months
Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA
Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends
Omeros Receives EMA CHMP Negative Opinion On Its Marketing Authorization Application For Narsoplimab For Treatment Of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
Cantor Fitzgerald Reiterates Overweight on Omeros, Maintains $22 Price Target
Omeros Transplant Drug Could Be Bigger than Expected, Says Analyst
Cantor Fitzgerald Upgrades Omeros to Overweight, Announces $22 Price Target
What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?
Omeros (OMER) Just Flashed Golden Cross Signal: Do You Buy?
Omeros (OMER) Q2 2026 Earnings Call Transcript
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.